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Highlights: 
 Antibodies were detectable by an in-house ELISA for at least 1.5 years in some infected cattle 
 Six out of 19 farms became low risk as the infection was resolved on them 
 Several diagnostic tools are required to assess biosecurity status of a herd 
 
 
 
 
Abstract 
Mycoplasma bovis causes bovine respiratory disease, mastitis, arthritis and otitis. The importance of 
M. bovis has escalated because of recent outbreaks and introductions into countries previously free 
of M. bovis. We characterized the course of M. bovis infection on 19 recently infected dairy farms 
over 24 months. Our objective was to identify diagnostic tools to assess the efficacy of control 
measures to assess low risk infection status on M. bovis infected farms. PCR assays and culture were 
used to detect M. bovis, and in-house and BioX ELISAs were used to follow antibody responses. 
Cows and young stock were sampled on four separate occasions, and clinical cases were sampled 
when they arose. On 17 farms, a few cases of clinical mastitis were detected, mostly within the first 
eight weeks after the index case. Antibodies detected by in-house ELISA persisted in the serum of 
cows at least for 1.5 years on all farms, regardless of the M. bovis infection status or signs of clinical 
disease or subclinical mastitis on the farm. Six out of 19 farms became low risk as the infection was 
resolved. Our results suggest that, for biosecurity purposes, regular monitoring should be conducted 
on herds by screening for M. bovis in samples from cows with clinical mastitis and calves with 
pneumonia, in conjunction with testing young stock by screening longitudinally collected nasal swabs 
for M. bovis and sequential serum samples for antibody against recombinant antigen.  
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1. Introduction 
Mycoplasma bovis, an important pathogen of cattle, is most commonly associated with bovine 
respiratory disease (BRD), mastitis, arthritis, keratoconjuctivitis and otitis media (Nicholas and 
Ayling, 2003). The importance of M. bovis infection has escalated over the past decade because of 
the increasing number of outbreaks in major dairy producing countries, its recent introduction into 
countries that were previously free of M. bovis, including New Zealand and Finland, and the 
occurrence of an outbreak caused by novel strain (Pothmann et al. 2015; Biosecurity New Zealand 
2018; Haapala et al. 2018). M. bovis significantly affects animal welfare and production and causes 
significant economic loss in both beef and dairy cattle industries (Nicholas and Ayling, 2003).  Efforts 
to develop efficacious vaccines against M. bovis have not been successful (Perez-Casal et al. 2017), 
with no commercial vaccines available throughout much of the world and only vaccines of 
questionable efficacy available in North America (Maunsell et al. 2011). Efforts to control the losses 
caused by M. bovis have led to increased use of antimicrobial drugs and recent reports suggest 
resistance to several antimicrobial drugs has increased in M. bovis (Ayling et al. 2014; Gautier-
Bouchardon et al. 2014; Heuvelink et al. 2016). Therefore, detection of infected cattle, especially 
subclinically infected animals, is of paramount importance in prevention of introduction of the agent 
into naïve herds and in the prevention of outbreaks (Caswell et al. 2007).  
Several studies have examined the prevalence of infection with M. bovis using either PCR assays to 
detect the organism and/or serological assays, including enzyme-linked immunosorbent assays 
(ELISAs), to detect antibodies against it (Assie et al. 2009; Bednarek et al. 2012; Arede et al. 2016; 
Wawegama et al. 2016). At an individual animal level, asymptomatic carriage and intermittent 
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shedding hamper reliable detection of the organism (Biddle et al. 2003; Hazelton et al. 2018). Infected 
animals may shed M. bovis for a few weeks to several months (Punyapornwithaya et al. 2010; 
Hazelton et al. 2018), but there is limited information about the circulation of M. bovis in an infected 
herd after natural infection and the antibody responses of animals in these infected herds. 
In Finland M. bovis was detected in 2012, even though rigorous diagnostic testing had been performed 
to detect it in BRD research project of calf rearing units in 2001 - 2003 (Autio et al. 2007) and in 
clinical BRD samples since then. Furthermore, extensive screening for mastitis pathogens in 
individual milk samples from cases of clinical and subclinical mastitis has been conducted for decades 
in Finland, with approximately 140,000 samples were tested in 2018 (there are approximately 
270,000 dairy cows in Finland). A multiplex PCR assay that included primers to detect M. bovis has 
been in use since early 2012. Between 2012 and 2018, 68 (0.8%) Finnish dairy herds were found to 
be infected with M. bovis.  
The low prevalence of M. bovis and the low population density of cattle in Finland make it a suitable 
platform for studying the course of infection with M. bovis at the herd level. Cattle industries 
throughout the world need improved strategies and tools for certification of farms that have a low risk 
of infection with M. bovis for biosecurity purposes. In this study, we aimed to identify the best 
diagnostic tools to track the efficacy of control measures to achieve a low risk of infection with M. 
bovis on infected farms. To do this we followed the course of M. bovis infection in 19 recently infected 
dairy farms over 24 months using real time PCR and culture to detect the organism, and serology to 
detect the antibody response to M. bovis, in the herds over the study period. We used several sampling 
techniques on the farms, including collection of bulk tank milk samples, individual sampling of both 
cows and young stock by collection of quarter milk samples, nasal swabs, nasopharyngeal swabs and 
serum samples, and collection of samples during post-mortem examinations. 
2. Materials and methods 
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Farms in the study 
Animal Health ETT has maintained a voluntary M. bovis control program in Finland since 2013, and 
all the infected dairy herds were encouraged to participate in the control program and the research 
project “Mycoplasma bovis in dairy herds”. The study included 19 infected dairy farms. Interviews 
and sampling were performed on each of these farms. Infection with M. bovis had not been detected 
previously on any of the farms, despite continuous mastitis pathogen testing (on 18 of the farms), 
including real time PCR for detection of M. bovis. On 17 farms the index cases were clinical mastitis 
confirmed by real time PCR, and on two farms the index cases were respiratory disease in calves. 
Table 1 shows the farm size, the management system, and the milk and post-mortem samples that 
were collected by farmers. The farms were advised to cull cows with mastitis caused by M. bovis, to 
avoid purchasing new animals, to house calves separately from the cows, and to follow appropriate 
hygiene measures. 
Sampling  
Veterinarians visited each of the farms four times, at approximately 6 month intervals, between 2014 
and 2017. The dates of the visits are shown in Table 2. During each visit, the veterinarian collected 
deep nasopharyngeal (NP) swabs and nasal (NS) swabs from calves between 1 week and 9 months 
of age and serum samples from all age groups. A total of 5 NP and 10 to 20 NS swabs were collected 
at each visit, depending on the number of calves on the farm. The NS swab (Transystem, Copan, 
Brescia, Italy) was collected from each calf prior to collection of the NP swab. NP swabs were 
collected using 27 cm long guarded swabs (Medical Wire Equipment Ltd., Corsham, England) and 
soaked in mycoplasma D broth (Friis and Krogh, 1983). In herds with a sufficient number of young 
stock, 15 serum samples were collected from each age group of young stock (3-6, 6-9 and 9-12 
months of age) and from cows, with a maximum 65 samples collected per herd. Farmers were advised 
to monitor cattle carefully for mastitis and other clinical signs and to submit quarter milk (QMS) 
samples from all cases of subclinical and clinical mastitis for real time PCR testing, and monthly bulk 
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tank milk (BTM) samples for real time PCR and in-house mycoplasma immunogenic lipase A (MilA) 
ELISA (Wawegama et al. 2014). As part of the study, the farms could send other clinical samples, 
including calves with disease suspected to have been caused by M. bovis for post-mortem 
examination, culture and confirmation of M. bovis by real time PCR. Table 1 shows the total number 
of samples submitted by farmers over the study period.     
Culture for M. bovis 
NP swabs and clinical samples were cultured. Samples in mycoplasma D broth were sub-cultured 
onto F-medium plates and diluted tenfold in F broth (Bölske et al. 1988). The broths were incubated 
at 37 °C for 3 - 5 days, and growth and color change monitored every second day. All broth cultures 
were examined for the presence of M. bovis by real-time PCR, and suspected positive cultures were 
sub-cultured onto F-medium plates. Plates were incubated in 5% CO2 at 37 °C for seven days, and 
inspected every second day under the microscope for mycoplasma colonies.  
DNA extraction and M. bovis real time PCR 
Nasal swabs and broth cultures were tested using a real time PCR assay targeting the oppD gene of 
M. bovis (CFX96 Touch Real-Time PCR Detection System, Bio-Rad Laboratories, CA, USA), as 
described previously (Sachse et al. 2010), with the minor modifications described by Haapala et al. 
(2018).  
QMS and BTM samples were analyzed by private laboratories using a commercial real time PCR 
assay for 16 mastitis pathogens, including M. bovis (Pathoproof® Complete 16-kit, Thermo Fisher 
Scientific, Finland), according to the manufacturer’s instructions. 
Detection of M. bovis-specific antibodies  
Two ELISAs were used to detect M. bovis-specific antibodies, the Bio K260 (Bio-X Diagnostics, 
Jemelle, Belgium) commercial ELISA and an in-house IgG-detection MilA ELISA (Wawegama et 
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al. 2014). This ELISA has an estimated animal-level sensitivity and specificity of 94.3% and 94.4%, 
respectively using a cut-off of 105 antibody units (AU) (Wawegama et al., 2016). The MilA ELISA 
was performed as described previously (Wawegama et al. 2014), with the concentration of M. bovis 
-specific antibodies in each sample calculated in antibody units (AU) by comparison with a series of 
standards on each plate using an ELISA analysis program (http://www.elisaanalysis.com), with a 
result of >135 AU interpreted as positive (Petersen et al. 2018). The Bio K260 ELISA was performed 
according to the manufacturer’s instructions.  
BTM samples collected at or near the sampling visits were also tested using the in-house MilA ELISA 
essentially as described previously, but at a 1/20 dilution. 
Grouping of the farms according to their infection status 
To analyze the dynamics of herd M. bovis-specific antibody concentrations, we classified the study 
farms into six infection status groups, based on the detection of M. bovis at each visit (Table 3). We 
considered a visit positive if M. bovis was detected on the farm by real time-PCR or culture of NP or 
NS swabs, or clinical, post-mortem or mastitis samples, with the status at each visit classified as 
positive or negative. We designated the infection status S0 (n = 2) if M. bovis was detected only in 
the index cases, and not thereafter; S1 (n = 4) if M. bovis was detected at the first sampling visit; S2 
(n = 2) if M. bovis was detected at the first two sampling visits; S3 (n = 4) if M. bovis was detected at 
the first three sampling visits; S4 (n = 3) if M. bovis was detected at all four sampling visits; and Sx 
( n = 4) if M. bovis was detected at more than one visit, but not consistently throughout the period the 
herd was positive. 
Statistical analysis 
All statistical analyses were carried out using GraphPad Prism Version 7.02. The significance of the 
differences in the proportions of positive animals at each visit in each infection group were calculated 
using a one-way ANOVA and Tukey's multiple comparison test. P < 0.05 was considered significant. 
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Median herd size was calculated, and Pearson’s correlation coefficient was calculated to assess the 
association between herd size and the infection status of the farms, and the association between the 
bulk tank milk anti-MilA and serum anti-MilA antibody concentrations of the cows. 
3. Results 
Clinical manifestations and detection of M. bovis 
On most of the farms the index case was clinical mastitis. There were only two farms on which no 
cases of mastitis caused by M. bovis were detected over the two year study period. On these farms 
the index cases were pneumonia in calves. On farms with M. bovis mastitis, only a few clinical 
mastitis cases were seen and these mainly (88%) occurred within the first eight weeks after the index 
case (Table 4). On most farms, cows with M. bovis mastitis were isolated, and slaughtered or culled 
as soon as possible after detection of infection. On one farm one cow was slaughtered later, at day 9 
after detection, but it was kept separated from other animals throughout this period. Table 4 shows 
the results from testing farms for M. bovis at each visit and the infection status of each of the herds.   
The farms were thoroughly examined for M. bovis over the 2 year study period (Tables 1, 2, 5). In 
total 3268 quarter milk samples were tested and only 51 cows had M. bovis mastitis. A total of 22 
samples from 10 farms were submitted for post-mortem examination. M. bovis was isolated from 12 
of these animals, from seven farms. PCR testing of 263 BTM samples, in total, yielded seven M. 
bovis positive samples, from five farms. All these positive samples, except for one, were collected 
within four weeks of the index mastitis case in the herd. On one farm (farm E), a single BTM sample 
was positive 5 months after the index case. After this positive finding, quarter milk samples from 
cows on farm E with elevated milk somatic cell counts were tested for M. bovis, and all were negative. 
Two cows with subclinical mastitis were dried off in the meantime without sampling. However, NS 
and NP swabs from calves on farm E were positive.   
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The median size of the herds was 61 cows and there was a positive, moderate correlation between 
herd size and the infection status of the farm (Pearson r = 0.6). On infection status S0 farms (n = 2) 
M. bovis was only detected in the index case and was not isolated at any other time throughout the 
study period. On four farms (infection status S1) M. bovis was detected only in the first half of the 
first year and on two farms (infection status S2) it was detected throughout the first year. On 11 farms 
(infection status S3, S4 or Sx) M. bovis was detected after the first year, and the majority of these 
farms had large herds in loose housing barns.  
Serum antibodies against M. bovis 
A total of 3317 serum samples were tested using two different ELISAs, using a cut-off values 135 
AU for the MilA ELISA and an ODC of 37% for the BioX ELISA (Table 5). The MilA ELISA 
detected more positive samples than the BioX ELISA. We analyzed the M. bovis specific antibody 
profiles for each infection status group using both ELISAs (Figs. 1 and 2). The proportions of MilA 
ELISA positive young stock had patterns similar to those detected by culture or PCR for M. bovis. In 
contrast, no such patterns were obtained with the BioX ELISA. There was a significant decrease in 
the proportion of young stock that were positive in the MilA ELISA after the first sampling visit (P 
< 0.05) on S0 and S1 farms (Fig. 1 a, b). Similarly, there was a significant decrease in the proportion 
of young stock that were positive in the MilA ELISA after the second visit on S2 farms (P < 0.05, 
Fig. 1 c). In contrast, on S3, S4 and Sx farms the proportion of young stock that were positive in the 
MilA ELISA remained as high as 80% at most time points, without any significant decrease in the 
proportion that were positive over the duration of the study (Fig. 1. d, e, f). However, 80 to 100% of 
cows were MilA ELISA positive throughout the duration of the study, regardless of the infection 
status of the farm. There were a few exceptions at a few time points, but no significant difference 
between the time points. On S0 farms, there was a significant decrease in the proportion of positive 
cows after the first visit, but the proportion had increased again by the third visit. On S4 and Sx farms, 
all the cows tested were positive in the MilA ELISA at the start of the project, and approximately 
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80% were positive at each time point thereafter (Fig. 1 e, f). No patterns were detectable in the BioX 
ELISA results from the different infection status groups (Fig. 2), possibly because the overall number 
of animals that were positive in the BioX ELISA was much lower than in the MilA ELISA. However, 
there was a significant decrease in the proportions of young stock and cows on S4 farms that were 
positive in the BioX ELISA after the first sampling (Fig. 2 e).  
Anti-M. bovis antibodies in bulk tank milk 
The concentrations of anti-M. bovis antibodies in the bulk tank milk samples (n = 68) were compared 
to the mean concentration of anti-M. bovis antibodies in the serum samples collected from the cows 
in the herd at the same visit over all four visits. There was a positive correlation between the anti-M. 
bovis antibody concentrations in the bulk tank milk samples and those in sera of the cows (r = 0.45), 
as measured using the MilA ELISA (Fig. 3).  
4. Discussion 
This is the first study to examine the circulation of M. bovis and the antibody responses against it in 
naturally infected dairy farms over a period of two years. We examined 19 farms for the presence of 
M. bovis using repeated individual mastitis milk and BTM sampling, and sampling of young stock by 
nasal and deep nasopharyngeal swabbing and collection of serum samples from young stock and cows 
on four occasions over two years.  
In the majority (88%) of the farms, clinical M. bovis mastitis was only detected over a short period, 
and the number of mastitis cases associated with M. bovis remained low. A short period of M. bovis 
mastitis could result in the early detection of mastitis and in a rapid response to remove the animals 
from the farm. Previous studies have found that the length of a mastitis outbreak can vary from two 
months to several years (Bayoumi et al. 1988; Mackie et al. 2000; Fox et al. 2003; Punyapornwithaya 
et al. 2012). On six farms (J, K, M, O, P and Q), M. bovis was not detected on three or more 
consecutive visits, with all milk samples (both QMS and BTM) negative for M. bovis over that time. 
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Clinical disease was resolved on these farms with herds having cleared M. bovis thus becoming low 
risk. These farms seemed to have not only resolved the clinical disease, but also seemed to have 
cleared the herd of M. bovis and thus achieved low risk status. Previous studies have demonstrated 
that herd size is a risk factor for M. bovis mastitis (Thomas et al. 1981; Fox et al. 2003; McCluskey 
et al. 2003; Lysnyansky et al. 2016).  All the herds in our study that appeared to have been cleared of 
M. bovis had fewer than 70 cows, and the majority of the farms in which infection persisted had larger 
herds though none exceeding 268. However, it has been shown that herds with over 500 cows are 
more vulnerable to mycoplasma mastitis than smaller herds (Nicholas et al. 2016). Several factors are 
associated with minimizing clinical disease and resolving outbreaks. Most of these are essentially 
management practices that minimize the risk of transmission, including separation of clinically 
affected animals from the herd, removal/culling of other infected animals, milking the hospital herd 
last and pasteurizing milk before feeding it to calves (Fox et al. 2003; Hazelton et al. 2018). To 
develop effective control strategies and M. bovis eradication programs, we need more investigations 
to characterize the most important farm management practices, to determine optimal biosecurity 
measures, and to determine the pathogen and host factors associated with clearance of M. bovis from 
a herd.  
Studies on M. bovis in dairy herds have focused on herds experiencing outbreaks of clinical mastitis 
(Hazelton et al. 2018; Petersen et al. 2018). In our study, the majority of the farms were infected, but 
had very few clinical cases, and could be therefore be defined as infected farms that were not 
experiencing an outbreak. On two farms (O and R), there were no M. bovis mastitis cases, even though 
M. bovis was circulating (Farm O, with an S1 infection status and Farm R with an Sx status). The 
cows had detectable serum antibodies against M. bovis, showing that they had been exposed to the 
pathogen but had not developed any signs of M. bovis mastitis. Similarly on two farms (A and E), M. 
bovis was circulating for over one year, but no M. bovis mastitis cases were seen after the index cases. 
Thus, continuous QMS testing of subclinical and clinical mastitis for M. bovis alone is not sufficient 
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to detect the presence of M. bovis in a herd, even though it is crucial for detection of cases of clinical 
mastitis. 
Routine identification of herds with M. bovis mastitis has typically been performed using BTM 
culture or PCR. The collection of BTM samples at intervals of 3 or 4 days is an effective way to 
screen for mycoplasma mastitis in dairy herds (Wilson et al. 2009). Screening for M. bovis in BTM 
has also been recommended as a biosecurity measure to reduce the risk of introduction of M. bovis 
into a naïve herd (Parker et al. 2017). In our study, PCR positive BTM samples were detected in only 
five (26%) of the herds, and only shortly after the initial mastitis cases, although M. bovis was still 
circulating in many of the herds for an extended time after this. Thus, a negative PCR test result on 
BTM is not an accurate method for determining the absence of M. bovis in a herd, and, therefore, is 
not suitable as the sole test for biosecurity screening, even though it is suitable for detecting M. bovis 
mastitis.  
Our study has shown that on all farms the majority of cows were seropositive in the MilA ELISA, 
with antibodies against M. bovis detected for at least for 1.5 years, regardless of the apparent ongoing 
presence or absence of M. bovis in the farm. Most previous studies have used other ELISAs and 
concluded that serum antibodies do not remain elevated for a prolonged period. Recently, Petersen et 
al. (2018) studied M. bovis infected cows using the BioX ELISA and showed that serum antibody 
levels generally declined within 2 months after the onset of clinical disease. They concluded that 
serology is unlikely to be useful for individual diagnosis of disease associated with M. bovis in dairy 
cows. In our study seropositive cows were detected using the BioX ELISA at most of the time points. 
However, after the second visit 20% or fewer of the cows or young stock were seropositive, regardless 
of the infection status of the farm. Therefore, the BioX ELISA results did not reflect the circulation 
of M. bovis in different infection status groups. However, these results were not unexpected, as the 
BioX ELISA has been found to have a much lower sensitivity than the MilA ELISA (Wawegama et 
al. 2016, Petersen et al. 2018).  
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Serum antibodies against M. bovis were detectable in the majority of the cows using the MilA ELISA 
throughout the study period. Strikingly, there was a clear decline in serum anti-MilA antibody 
concentrations in young stock on the farms on which infection was under control, and on which M. 
bovis was not detected in the second year after the index case. In contrast, on S3, S4 and Sx farms, 
where M. bovis circulated for more than 1.5 years, 60 to 80% of young stock remained seropositive. 
Serological diagnosis alone indicates past exposure rather than current infection (Nicholas and 
Ayling, 2003). Nevertheless, our study suggests that sequential testing of different age groups for 
antibodies against M. bovis can be used to assess the M. bovis infection status of a herd and the trend 
towards clearance of infection from a herd to achieve a low risk M. bovis status. There was also a 
correlation between the serum antibody concentrations of the cows in a herd and the BTM antibody 
concentrations. This suggests that BTM antibodies may reflect not only antibodies produced in the 
udder but also those in the serum, or alternatively that intramammary infections with M. bovis can 
induce a detectable systemic immune response. More investigation of appropriate cut-off values and 
robust interpretations for use of the MilA ELISA for testing BTM would result in a powerful 
diagnostic tool for following the infection status of herds for eradication or control of M. bovis in 
dairy herds. 
Previous studies have shown that during an initial outbreak of M. bovis mastitis, colonization of 
distant sites in the body may be common in cows, but that this decreases rapidly (Punyapornwithaya 
et al. 2010; Hazelton et al. 2018). Thus, timing of sampling in relation to a recent outbreak appears 
to be of considerable importance and sampling of body sites by nose, eye, or vaginal swabs of cows 
is ineffective in evaluating the presence of M. bovis in the herd. In our study, we did not directly test 
for the colonization of cows with M. bovis, but the high levels of antibodies against M. bovis in cows 
on farms without ongoing disease appears likely to reflect frequent asymptomatic infection with M. 
bovis. Moreover, in young stock the patterns of seropositivity appeared to reflect the presence of the 
pathogen.  
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Calves are believed to shed M. bovis in respiratory secretions and thus to transmit infection through 
continued close contact (Nicholas, 2011). In our study, the prevalence of detection of M. bovis in 
calves ranged from 0 to 75% on different visits. On several farms, M. bovis was detected in nasal and 
nasopharyngeal swabs from calves when there had not been any cases of clinical M. bovis mastitis in 
cows in the previous months. It has been shown that the within-herd prevalence of detection of M. 
bovis in nasal swabs from calves is generally high (up to 100%) in herds with a history of an outbreak, 
and low in herds that have not experienced an outbreak (Maunsell and Donovan, 2009). These results, 
combined with our findings, emphasize that effective biosecurity screening requires repeated 
monitoring of calves to ensure that the presence of M. bovis on a farm is detected. 
For the biosecurity purposes, it is critically important to prevent introduction of M. bovis into a herd 
by purchasing animals from farms shown to be free of infection. Shedding of M. bovis has shown to 
be intermittent (Caswell et al. 2007; Maunsell et al. 2011). Therefore, a single test of an individual 
animal is not reliable, and the infection status of the herd needs to be determined by sequential testing 
using serology and PCR. There is no gold standard for sampling and testing asymptomatic animals. 
In this study, we could not interpret the Bio-X ELISA results with respect to the infection status of 
the herds, as similar levels of seropositivity were seen in herds whether there was ongoing circulation 
of M. bovis or not. Similarly, although the MilA ELISA results appeared to mirror the infection status 
of the young stock, the proportion of cows that were seropositive cows was high in all infection status 
groups and thus these animals may not be the best sentinels for biosecurity screening. In conclusion, 
our study suggests that regular monitoring for M. bovis in samples from cows with mastitis and calves 
with pneumonia, combined with longitudinal sampling of young stock by nasal swabbing for PCR 
and for serum for testing in the MilA ELISA, and potentially testing bulk tank milk for antibodies 
against M. bovis using the MilA ELISA, provide suitable diagnostic tools for biosecurity screening 
and control programs.  
5. Conclusions 
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If control of M. bovis is to be improved, it is critically importance to prevent the introduction of M. 
bovis into herds by purchasing animals from farms that are free of infection. Testing of individual 
animals or herds on a single occasion is not reliable, so the infection status of the herd needs to be 
based on sequential testing of herds. Our results suggest that optimal assurance of the infection status 
of herds can only be achieved by regular monitoring for M. bovis in samples from clinical cases of 
mastitis and calf pneumonia, combined with longitudinal collection from young stock of nasal swabs 
for detection of M. bovis by PCR testing and sera for detection of antibodies against M. bovis using 
the MilA ELISA. 
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Figure 1. Proportions of animals seropositive over time in herds with different statuses of infection 
using the MilA ELISA. a) infection status S0, b) infection status S1, c) infection status S2, d) infection 
status S3, e) infection status S4, f) infection status Sx. 
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Figure 2. Proportions of animals seropositive over time in herds with different statuses of infection 
using the BioX ELISA. a) infection status S0, b) infection status S1, c) infection status S2, d) infection 
status S3, e) infection status S4, f) infection status Sx. 
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Figure 3. Correlation between mean serum antibody concentrations (AU) of the cows in each herd 
and the bulk tank milk antibody concentration at the same collection time points using the MilA 
ELISA. Line represents r = 0.45 
 
 
Table 1. Description of herds and number of milk and post-mortem samples collected by farmers. 
      Sample types, method, no of samples tested for M. bovis 
Herd ID 
No of 
cows 
Barn type 
QMS1  Bulk tank milk  Post mortem 
PCR  PCR ELISA  Culture 
A 47 tie-stall housing 64  16 4    
B 61 loose housing 252  16 4   2 
C 183 loose housing 154  4 2   2 
D 268 loose housing 500  2 2    
E 25 loose housing 27  16 4    
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F 50 tie-stall housing 28  18 4   1 
G 157 loose housing 487  19 3    
H 60 loose housing 194  17 4   3 
I 100 loose housing 96  17 3    
J 61 loose housing 595  22 4    
K 29 tie-stall housing 51  12 4   1 
L 41 tie-stall housing 51  6 3    
M 66 loose housing 112  18 4   1 
N 158 loose housing 309  15 4   4 
O 48 loose housing 94  13 4   1 
P 18 tie-stall housing 12  11 4    
Q 28 tie-stall housing 30  18 4    
R 66 loose housing 36  12 4   1 
S 127 loose housing 176   11 3   6 
1QMS=quarter milk sample. Farmers were advised to monitor cattle for mastitis and other clinical 
signs thoroughly and to submit samples for testing for mastitis pathogens in all cases of subclinical 
and clinical mastitis by quarter milk sampling. Some farmers also submitted samples from clinically 
normal animals.  
 
Table 2. Infection status at each visit to each herd based on detection of M. bovis.  
                          
      Visit 1  Visit 2  Visit 3  Visit 4 
 
      No. positive/total2      
No. 
positive/total 
     No. positive/total      
No. 
positive/total 
Herd  Index case 
Infection 
status1 
Date of visit 
Infection 
status1 
No. infected 
calves 
NS NP   Date of visit 
Infection 
status 
No. infected 
calves 
NS NP   Date of visit 
Infection 
status 
No. infected 
calves 
NS NP   Date of visit 
Infection 
status 
No. infected 
calves 
NS NP 
A 29th Apr 2014 S3 10th Nov 2014 + 2/19 2/19 2/5  4th May 2015 + 3/15 1/15 2/6  10th Nov 2015 + 1/21 1/21 0/5  23rd May 2016 - 0/19 0/19 0/5 
B 21st Apr 2015 S2 19th May 2015 + 11/19 10/19 4/5  24th Nov 2015 + 3/23 3/23 0/5  17th May 2016 - 0/23 0/23 0/5  21st Nov 2016 - 0/19 0/19 0/5 
C 14th Jan 2016 S4 25th Jan 2016 + 11/20 10/20 4/5   24th Aug 2016 + 12/20 12/20 3/5  15th Feb 2017 + 4/19 3/19 1/5  29th Aug 2017 + 1/20 1/20 0/5 
D 12th Aug 2013 S4 8th Oct 2013 + 24/50 24/50 ND   10th Dec 2014 + 10/20 10/20 2/5  8th Sept 2015 + 2/20 2/20 2/10  22nd Mar 2016 + 8/21 7/21 1/5 
E 10th Mar 2015 S3 30th Mar 2015 + 9/15 9/15 3/5   19th Oct 2015 + 1/9 0/9 1/5  25th Apr 2016 + 6/12 4/12 5/5  24th Oct 2016 - 0/13 0/13 0/5 
F 12th May 2015 S2 27th May 2015 + 4/11 4/11 1/5   1st Dec 2015 + 3/16 2/16 2/5  18th May 2016 - 0/13 0/13 0/5  23rd Nov 2016 - 0/13 0/13 0/5 
G 15th Jan 2016 Sx 21st Feb 2016 + 10/20 10/20 3/5   1st Sept 2016 - 0/20 0/20 0/5  28th Feb 2017 + 3/19 3/19 0/5  22nd Aug 2017 - 0/20 0/20 0/5 
H 5th Nov 2015 Sx 14th Dec 2015 + 4/15 3/15 3/5   8th June 2016 + 9/19 9/19 3/5  12th Dec 2016 - 0/14 0/14 0/5  20th June 2017 + 1/19 1/19 0/5 
I 23rd Dec 2015 S3 3rd Feb 2016 + 3/19 2/19 1/5   9th Aug 2016 + 6/18 6/18 4/5  7th Feb 2017 + 1/20 1/20 0/5  23rd Aug 2017 - 0/20 0/20 0/5 
J 11th Dec 2015 S1 11th Jan 2016 + 15/20 14/20 4/5   12th July 2016 - 0/18 0/18 0/5  3rd Jan 2017 - 0/27 0/27 0/5  4thJuly 2017 - 0/20 0/20 0/5 
K 17th Jul 2014 S0 11th Nov 2014 - 0/6 0/6 0/5   11th May 2015 - 0/8 0/8 0/5  24th Nov 2015 - 0/9 0/9 0/5  24th May 2016 - 0/7 0/7 0/5 
L 24th May 2014 Sx 10th June 2014 + 7/21 7/21 6/6   27th Nov 2014 - 0/20 0/20 0/5  25th May 2015 + 9/20 9/20 3/5  16th Nov 2015 + 7/14 7/14 0/5 
M 29th Aug 2014 S0 12th Nov 2014 - 0/9 0/9 0/5   11th May 2015 - 0/15 0/15 0/6  25th Nov 2015 - 0/18 0/18 0/5  24th May 2016 - 0/13 0/13 0/5 
N 18th Mar 2015 S3 15th Apr 2015 + 11/23 9/23 2/5   10th Nov 2015 + 16/25 14/25 4/5  16th May 2016 + 11/20 8/20 4/5  22nd Nov 2016 - 0/20 0/20 0/5 
O 31st Mar 2015 S1 28th Apr 2015 + 4/16 4/16 0/6   3rd Nov 2015 - 0/19 0/19 0/5  26th Apr 2016 - 0/19 0/19 0/5  21st Nov 2016 - 0/15 0/15 0/5 
P 29th Oct 2015 S1 25th Nov 2015 + 1/6 1/6 0/5   31st May 2016 - 0/9 0/9 0/4  29th Nov 2016 - 0/8 0/8 0/5  16th May 2017 - 0/7 0/7 0/5 
Q 12th Aug 2015 S1 9th Sept 2015 + 2/19 2/19 0/5   16th Mar 2016 - 0/15 0/15 0/5  20th Sept 2016 - 0/11 0/11 0/5  14th Mar 2017 - 0/12 0/12 0/5 
R 1st Sept 2015 Sx 20th Oct 2015 + 5/20 5/20 3/5   18th Apr 2016 - 0/21 0/21 0/5  17th Oct 2016 - 0/18 0/18 0/5  4th Apr 2017 + 13/21 10/21 5/5 
S 25th Jan 2016 S4 16th Feb 2016 + 8/11 8/11 5/5   16th Aug 2016 + 7/20 6/20 4/5   13th Feb 2017 + 5/20 3/20 3/5   8th Aug 2017 + 1/15 0/15 1/4 
 
1 S0 = Mb detected in index case. S1 = Mb detected in index case and at first visit. S2 = Mb detected 
in index case and at first and second visits. S3 = Mb detected in index case and at first, second and 
third visits. S4 = Mb detected in index case and at all subsequent visits Sx=Mb detected intermittently. 
2 No. of samples. NS = nasal swab. NP = nasopharyngeal swab. ND = not done. 
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Table 3. Classification of the infection status of herds based of detection on M. bovis at repeated 
sampling visits.    
Infection status Visit 1 Visit 2 Visit 3 Visit 4 Herd 
S0 1 - - - - K, M 
S1 + - - - J, O, P, Q 
S2 + + - - B, F 
S3 + + + - A, E, I, N 
S4 + + + + C, D, S 
Sx + - + - G 
Sx + + - + H 
Sx + - + + L 
Sx + - - + R 
1 S1 = Mb detected in index case and at first visit. S2 = Mb detected in index case and at first and 
second visits. S3 = Mb detected in index case and at first, second and third visits. S4 = Mb detected 
in index case and at all subsequent visits Sx = Mb detected intermittently. 
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Table 4. Detection of M. bovis infection and M. bovis mastitis during the study period. 
Herd Index case 
Infection 
status 
No. M. bovis 
mastitis 
cases 
Week 1 Weeks 2 - 8 Weeks 8 - 26 Weeks 27 - 52 
After 53 
weeks 
A Mastitis S3 1 1     
B Mastitis S2 2 1 1    
C Mastitis S4 8 3 4 1   
D Mastitis S4 6 1 3   2 
E Mastitis S3 1 1     
F Mastitis S2 1 1     
G Mastitis Sx 1 1     
H Mastitis Sx 4 1 3    
I Mastitis S3 7 1 4 2   
J Mastitis S1 3 1 2    
K Mastitis S0 1 1     
L Mastitis Sx 1 1     
M Mastitis S0 1 1     
N Mastitis S3 7 2 4  1  
O Calf pneumonia S1 0      
P Mastitis S1 2 1 1    
Q Mastitis S1 1 1     
R Calf pneumonia Sx 0      
S Mastitis S4 4 1 3    
  Total (%) 51 20 (39 %) 25 (49 %) 3 (6 %) 1 (2 %) 2 (4 %) AC
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Table 5. Results from testing individual serum samples for antibodies against M. bovis using the 
BioX and MilA ELISAs (number positive/total number of samples). 
   Visit 1  Visit 2  Visit 3  Visit 4 
Herd   BioX MilA  BioX MilA  BioX MilA  BioX MilA 
A  2/36 33/36  2/37 20/37  2/38 25/38  1/37 7/37 
B  10/54 46/54  5/57 54/57  5/61 33/61  1/47 21/47 
C  27/61 54/61  8/61 53/61  5/60 60/60  19/61 57/61 
D  15/30 29/30  9/59 48/59  7/60 53/60  6/60 60/60 
E  7/32 31/32  5/30 24/30  3/28 26/28  3/30 22/30 
F  17/30 24/30  4/26 22/26  2/30 23/30  0/31 17/31 
G  1/61 36/61  5/60 40/60  1/55 54/55  10/47 42/47 
H  23/38 38/38  7/30 27/30  2/39 31/39  1/31 14/31 
I  8/53 45/53  17/44 40/44  3/41 36/41  19/53 50/53 
J  18/36 30/36  5/41 28/41  3/34 19/34  2/36 10/36 
K  0/25 22/25  2/22 11/22  2/26 16/26  2/26 9/26 
L  17/29 29/29  0/44 30/44  3/45 42/45  7/38 33/38 
M  2/35 34/35  3/34 16/34  4/43 16/43  0/40 16/40 
N  26/65 54/65  18/64 53/64  4/60 60/60  2/60 41/60 
O  4/31 27/31  2/32 13/32  1/35 28/35  1/35 20/35 
P  2/19 16/19  3/21 15/21  2/24 17/24  1/21 11/21 
Q  7/32 28/32  5/31 24/31  3/33 13/33  1/31 15/31 
R  8/42 36/42  3/43 24/43  3/32 14/32  8/46 38/46 
S  11/17 15/17  14/35 33/35  7/30 29/30  2/22 22/22 
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